NBP
NovaBridge Biosciences American Depositary Shares (NBP)
Healthcare • NASDAQ • $2.20-0.90%
- Symbol
- NBP
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.20
- Daily Change
- -0.90%
- Market Cap
- $254.43M
- Trailing P/E
- N/A
- Forward P/E
- -2.08
- 52W High
- $6.79
- 52W Low
- $0.85
- Analyst Target
- $8.00
- Dividend Yield
- N/A
- Beta
- 1.56
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which is in Phase 2b clinical trail for Wet AMD and other retinal diseases; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. The company has a strategic licensing agreement with AffaMed and AskGene to develop and commercialize VIS-101 to Visara. It also has collaborations with Bristol Myers Squibb for t…
Company websiteResearch NBP on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.